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Value of the dataOrtiz-Andrade R. (2016) [1]. Toxicity was predicted through the ACD/
ToxSuite software and evaluated in vivo using brine shrimp larvae
(Artemia salina L.) and mice. Also, we used the micronucleus assay to
determine genotoxicity. We used the platform admetSAR to predict
absorption properties of LIA and lidocaine.
& 2016 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Specifications Tableubject area Pharmacology, Toxicology
ore specific sub-
ject areaAcute toxicity, cardiovascular responseype of data Table, figure
ow data was
acquiredAdmetSAR and ACD/ToxSuite software
Pharmacological and toxicological assays in vivoata format Analyzed
xperimental
factorsDrugs were administered to mice by the oral route and toxicity parameters
were observed at 14 days. Heart rate, systolic and diastolic blood pressure
were evaluated in ratsxperimental
featuresCardiovascular responses were measured with the Panlab Non-Invasive
Blood Pressure System for Rodents and Dogs (Harvard Apparatus)
Platform admetSAR, ACD/ToxSuite software, GraphPad Prism 5.0ata source
locationMexico City, Mexicoata accessibility Data found in this articleD These data are useful to demonstrate that LIA, a new analog of lidocaine, is not toxic in Brine Ship
and mice.
 LIA is not genotoxic compound in mice.
 This drug, in contrast to lidocaine, does not modify cardiovascular responses.
 LIA absorption (blood brain barrier permeability and intestinal absorption) predicted is 30% similar
to that observed with lidocaine.
1. Data
Table 1 shows theoretical predictive values of toxicity of lidocaine and LIA determined by the ACD/
ToxSuite software.
Fig. 1 depicts preliminary data of toxicity assayed in Brine Ship (Artemia saline L.). Table 2 describes
acute toxicity in two phases by the Lorke method in mice. Table 3 depicts acute genotoxicity in mice.
Fig. 2 shows the cardiovascular effects of LIA and lidocaine in rats.
Table 4 depicts predictive absorption values of LIA and lidocaine.
2. Experimental design, materials and methods
2.1. Acute toxicity study
2.1.1. Acute toxicity parameters of LIA and lidocaine were computed with the ACD/ToxSuite software (v.
2.95) (Table 1)
M. Déciga-Campos et al. / Data in Brief 8 (2016) 1007–1012 10092.1.2. Artemia saline lethality test
LIA and lidocaine were evaluated for lethality in brine shrimp larvae (Artemia saina L.) according to
the procedure described previously [2]. Each concentration of either LIA or lidocaine (100, 200, 400,
800 and 1000 ppm) was assayed in triplicate. The surviving shrimp were counted after 24 h and the
percentage of deaths was determined by the computation of half lethal concentration 50 (LC50)
(Fig. 1).
2.1.3. Toxicity in mice by Lorke method
Experiments were performed on ICR male mice by the Lorke method [3]. Doses were selected
according this method. In both phases, mice were observed daily for 14 days for mortality, toxic
effects and behavioral changes. Restlessness, respiratory distress, seizures, diarrhea, motor activity,
posture and reflexes were qualitatively determined. Body weight was also monitored. The internal
organs (including the stomach, heart, lung, liver, and kidneys) were removed at the end of experiment
and visually examined for lesions. Neither LIA nor lidocaine produced visible macroscopically
damage.
2.1.4. Determination of genotoxicity by the bone marrow micronucleus assay
This test was carried out following standard protocols [4,5]. Briefly, ICR male mice (25–30 g) were
injected with cyclophosphamide (40 mg/kg, i.p.), as positive control, LIA (100 mg/kg, i.p.), lidocaine
(100 mg/kg, i.p.) or vehicle (saline solution, 0.9%, i.p). Animals were sacrificed 24 h later and the bone
marrow from both femurs was flushed out using 2 mL of saline and centrifuged for 5 min at
3000 rpm. The supernatant was discarded, and the pellet was re-suspended in 0.3 mL of saline. Of
this smears were made on glass slides. The slides were fixed with methanol and stained with 10%
Wright–Giemsa stain. Cells were blindly scored using a light microscope at 100 X magnification. For
the analysis of micronucleated cells, 1000 polychromatic erythrocytes (PCE) per animal were scored.
In order to assess the cytotoxic effects of compounds, the ratio of PCE to normochromatic ery-
throcytes (NCE) was determined in 1000 erythrocytes [4,5]. The results are presented as the mean
number of micronucleated polychromatic erythrocytes (MNPCE) or the ratio PCE:NCE in individual
mice (two smears per animal)7SEM for five animals per group (Table 3).
2.2. Cardiovascular response in rats
The hypotensive activity was determined using a standard protocol of Avila-Villarreal et al. [6].
This study was conducted in normotensive rats. Animals were allotted into four groups (of six ani-
mals) as follows: control rats (SS, group 1), and positive control (diltiazem, group 2), LIA (group 3) and
lidocaine (group 4). Treated groups were administered with diltiazem (calcium channel blocker;
30 mg/kg, p.o.), LIA (50 and 80 mg/kg, p.o.) and lidocaine (50 and 80 mg/kg, p.o.). Systolic and dia-
stolic blood pressure as well as heart rate were recorded before and after treatment at 0, 1, 3, 5 and
7 h by the tail cuff method using a Panlab non-invasive blood pressure system for rodents and dogs
(Harvard Apparatus). Percent of reduction in heart rate (HR), systolic blood pressure (SBP) or diastolic
blood pressure (DBP) were calculated using diltiazem as control (Fig. 2).Table 1
Toxicity profiles predicted for LIA and lidocaine by the ACD/ToxSuite software.
Compound LD50 (mg/kg) Probability of inhibition
(IC50o10 μM)
Mouse Rat CYP-450 Isoform hERG
i.p. p.o. i.p. p.o. 3A4 2D6 1A2
LIA 290 460 290 1900 0.01 0.16 0.01 0.69
Lidocaine 130 440 130 700 0.01 0.14 0.05 0.05
Artemia saline L.
LIA
LC50 = 335.1 ±85.7 ppm
Lidocaine
LC50 = 265.2 ± 24.4 ppm
Fig. 1. Toxicity of LIA and lidocaine in Brine Ship (Artemia saline L.).
Table 2
Acute toxicity in mice by the Lorke Method.
Compound Doses (mg/kg, i.p.) Dead mice
Lidocainen
Phase I 10 0/3
100 0/3
1000c 3/3
Phase II 140 1/3
225c 1/3
370c 3/3
600c 3/3
LIAnn
Phase I 10 0/3
100 0/3
1000 3/3
Phase II 140 0/3
225 0/3
370 0/3
600 3/3
n LD50 for lidocaine¼570 mg/kg, i.p.
nn LD50 for LIA¼800 mg/kg, i.p.
c Mice presented seizures before death.
Table 3
Acute genotoxic effects of LIA and lidocaine in the bone marrow micronucleus test in mice.
Treatment Dose (mg/kg, i.p.) MNPCE per 1000 PCE PCE:NCE
Vehicle — 0 22.871.3#
LIA 100 5.871.9n,# 20.771.6#
Lidocaine 100 4.672.1n,# 19.571.4#
Cyclophosphamide 40 82.671.8# 1470.3*
MNPCE: Micronucleated polychromatic erythrocytes.
PCE: Polychromatic erythrocytes.
NCE: Normochromatic erythrocytes.
n Significantly different from cyclophosphamide (po0.05).
# Significantly different from vehicle (po0.05).
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Fig. 2. Maximal decrease in (A) systolic blood pressure, (B) diastolic blood pressure and (C) heart rate elicited by oral
administration of 50 and 80 mg/kg of LIA and lidocaine in conscious rats. Results are expressed as the mean and S.E.M, n¼6 rats
per group, *po0.05 compared with lidocaine, by repeated measures one-way analysis of variance.
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We used the platform admetSAR [7] to calculate human intestinal absorption, blood–brain barrier
penetration, Caco-2 permeability, renal organic cation transporter, P-glycoprotein substrate and
inhibitor. These properties play key roles in the discovery/development of drugs (Table 4). The
software predicted high values of blood–brain barrier permeability and intestinal absorption for LIA.
However, the software predicted a moderate permeability for LIA in Caco-2 cells. Furthermore, the
Table 4
Predictive pharmacokinetic values calculated with admetSAR for the most active compounds.
Model Probability of property of compounds
LIA Lidocaine
Blood–brain barriera (þ) 0.9541 (þ) 0.9688
Human intestinal absorptionb (þ) 0.9565 (þ) 1.000
Caco-2 permeabilityc (þ) 0.6075 () 0.6318
P-glycoprotein substrated (Y) 0.8415 (Y) 0.5806
P-glycoprotein inhibitore (N) 0.7956 (N) 0.8910
Renal organic cation transportere (N) 0.5159 (N) 0.5776
a (þ) High BBB permeability; () moderate-poor BBB permeability.
b (þ) More than 30%; () less than 30%.
c (þ) High Caco-2 permeability; () moderate-poor Caco-2 permeability.
d (Y) Substrate, (N) Non-substrate.
e (Y) Inhibitor, (N) Non-inhibitor.
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compound could have easily cleared from cells. The software also predicted that LIA is not an inhibitor
of renal organic cation transporter.Acknowledgments
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